At Aiolos Bio, we are dedicated to revolutionizing the treatment landscape for respiratory disease and other immunological disorders. Our goal is to provide patients and caregivers with more efficacious therapies that significantly reduce treatment burden. Our vision is embodied in our current focus – the development of a groundbreaking anti-TSLP therapy with best-in-class potential.

We are a San Francisco Bay area-based clinical stage biopharma company with additional operations in London, UK. The Aiolos team is comprised of seasoned drug developers, who have successfully developed and launched products for a range of immune conditions, including asthma, rheumatoid arthritis, IPF, and more. As we grow, we will look to add like-minded individuals to our team - those committed to the goal of providing a meaningful difference in the lives of patients suffering from respiratory illnesses and other immune disorders.

Pharmaceutical

Life Sciences

Biotechnology

Aiolos Bio

Khurem Farooq

Chris Clevenger

Michael Gladstone

Amir Zamani

Tapan Maniar

Sosei Heptares

Jane Hughes

Ashley Taylor

The Leadership Team at Aiolos Bio sets the strategic direction and oversees the execution of company-wide initiatives to advance their groundbreaking anti-TSLP therapy and other immunological treatments. Comprised of top executives, the team ensures alignment across scientific, technical, commercial, and operational functions, fostering a cohesive approach to achieving the company's mission of revolutionizing treatments for respiratory and immunological disorders.

Leadership Team

Clinical Operations

Leadership Team

About

Team members

Other teams at Aiolos Bio

Clinical Operations